An open trial of OKT3 in patients with multiple sclerosis

Brian G Weinshenker, B. Bass, S. Karlik, G. C. Ebers, G. P A Rice

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

We report our experience with treatment with Muromonab-CD3 (Orthoclone OKT3) of 16 patients with multiple sclerosis (MS) who were in a progressive phase of their disease (n = 13) or in an acute severe attack lasting longer than 1 month without recovery (n = 3). We induced acute severe T-cytopenia with OKT3. Fifteen patients completed treatment for 10 days. Side effects were common and severe and included hypotension, nausea and vomiting, diarrhea, fever, and myalgia. In two of two patients tested, there was a transient though major rise in the levels of interferon gamma and tumor necrosis factor in the first 12 hours of treatment. Nonetheless, we did not detect new clinical or MRI activity of MS during the period of treatment, although many patients deteriorated transiently in disability scores. At the conclusion of follow-up, only four patients had deteriorated by 1.0 or more points on the Expanded Disability Status Scale of Kurtzke (EDSS) (73% stabilization rate). Of those patients who deteriorated, two died of complications of MS (EDSS 10). Only two patients had clinical improvement at 1 year follow-up. The attendant toxicity of OKT3 makes it unlikely that it will play a major role in the treatment of MS.

Original languageEnglish (US)
Pages (from-to)1047-1052
Number of pages6
JournalNeurology
Volume41
Issue number7
StatePublished - 1991
Externally publishedYes

Fingerprint

Muromonab-CD3
Multiple Sclerosis
Therapeutics
Myalgia
Hypotension
Nausea
Interferon-gamma
Vomiting
Diarrhea
Fever
Tumor Necrosis Factor-alpha

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Weinshenker, B. G., Bass, B., Karlik, S., Ebers, G. C., & Rice, G. P. A. (1991). An open trial of OKT3 in patients with multiple sclerosis. Neurology, 41(7), 1047-1052.

An open trial of OKT3 in patients with multiple sclerosis. / Weinshenker, Brian G; Bass, B.; Karlik, S.; Ebers, G. C.; Rice, G. P A.

In: Neurology, Vol. 41, No. 7, 1991, p. 1047-1052.

Research output: Contribution to journalArticle

Weinshenker, BG, Bass, B, Karlik, S, Ebers, GC & Rice, GPA 1991, 'An open trial of OKT3 in patients with multiple sclerosis', Neurology, vol. 41, no. 7, pp. 1047-1052.
Weinshenker BG, Bass B, Karlik S, Ebers GC, Rice GPA. An open trial of OKT3 in patients with multiple sclerosis. Neurology. 1991;41(7):1047-1052.
Weinshenker, Brian G ; Bass, B. ; Karlik, S. ; Ebers, G. C. ; Rice, G. P A. / An open trial of OKT3 in patients with multiple sclerosis. In: Neurology. 1991 ; Vol. 41, No. 7. pp. 1047-1052.
@article{b9fad439eabe4972b0d4ab29da5af95c,
title = "An open trial of OKT3 in patients with multiple sclerosis",
abstract = "We report our experience with treatment with Muromonab-CD3 (Orthoclone OKT3) of 16 patients with multiple sclerosis (MS) who were in a progressive phase of their disease (n = 13) or in an acute severe attack lasting longer than 1 month without recovery (n = 3). We induced acute severe T-cytopenia with OKT3. Fifteen patients completed treatment for 10 days. Side effects were common and severe and included hypotension, nausea and vomiting, diarrhea, fever, and myalgia. In two of two patients tested, there was a transient though major rise in the levels of interferon gamma and tumor necrosis factor in the first 12 hours of treatment. Nonetheless, we did not detect new clinical or MRI activity of MS during the period of treatment, although many patients deteriorated transiently in disability scores. At the conclusion of follow-up, only four patients had deteriorated by 1.0 or more points on the Expanded Disability Status Scale of Kurtzke (EDSS) (73{\%} stabilization rate). Of those patients who deteriorated, two died of complications of MS (EDSS 10). Only two patients had clinical improvement at 1 year follow-up. The attendant toxicity of OKT3 makes it unlikely that it will play a major role in the treatment of MS.",
author = "Weinshenker, {Brian G} and B. Bass and S. Karlik and Ebers, {G. C.} and Rice, {G. P A}",
year = "1991",
language = "English (US)",
volume = "41",
pages = "1047--1052",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - An open trial of OKT3 in patients with multiple sclerosis

AU - Weinshenker, Brian G

AU - Bass, B.

AU - Karlik, S.

AU - Ebers, G. C.

AU - Rice, G. P A

PY - 1991

Y1 - 1991

N2 - We report our experience with treatment with Muromonab-CD3 (Orthoclone OKT3) of 16 patients with multiple sclerosis (MS) who were in a progressive phase of their disease (n = 13) or in an acute severe attack lasting longer than 1 month without recovery (n = 3). We induced acute severe T-cytopenia with OKT3. Fifteen patients completed treatment for 10 days. Side effects were common and severe and included hypotension, nausea and vomiting, diarrhea, fever, and myalgia. In two of two patients tested, there was a transient though major rise in the levels of interferon gamma and tumor necrosis factor in the first 12 hours of treatment. Nonetheless, we did not detect new clinical or MRI activity of MS during the period of treatment, although many patients deteriorated transiently in disability scores. At the conclusion of follow-up, only four patients had deteriorated by 1.0 or more points on the Expanded Disability Status Scale of Kurtzke (EDSS) (73% stabilization rate). Of those patients who deteriorated, two died of complications of MS (EDSS 10). Only two patients had clinical improvement at 1 year follow-up. The attendant toxicity of OKT3 makes it unlikely that it will play a major role in the treatment of MS.

AB - We report our experience with treatment with Muromonab-CD3 (Orthoclone OKT3) of 16 patients with multiple sclerosis (MS) who were in a progressive phase of their disease (n = 13) or in an acute severe attack lasting longer than 1 month without recovery (n = 3). We induced acute severe T-cytopenia with OKT3. Fifteen patients completed treatment for 10 days. Side effects were common and severe and included hypotension, nausea and vomiting, diarrhea, fever, and myalgia. In two of two patients tested, there was a transient though major rise in the levels of interferon gamma and tumor necrosis factor in the first 12 hours of treatment. Nonetheless, we did not detect new clinical or MRI activity of MS during the period of treatment, although many patients deteriorated transiently in disability scores. At the conclusion of follow-up, only four patients had deteriorated by 1.0 or more points on the Expanded Disability Status Scale of Kurtzke (EDSS) (73% stabilization rate). Of those patients who deteriorated, two died of complications of MS (EDSS 10). Only two patients had clinical improvement at 1 year follow-up. The attendant toxicity of OKT3 makes it unlikely that it will play a major role in the treatment of MS.

UR - http://www.scopus.com/inward/record.url?scp=0026018158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026018158&partnerID=8YFLogxK

M3 - Article

C2 - 1906145

AN - SCOPUS:0026018158

VL - 41

SP - 1047

EP - 1052

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -